Los Angeles – – September 10, 2026 -- Schall, Brown & Schwartz LLP has filed a federal securities class action against Beta Bionics, Inc. (NASDAQ: BBNX), alleging the company misled investors about FDA findings tied to its iLet Bionic Pancreas insulin pump. The case, Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999, is pending in the U.S. District Court for the Central District of California.
Class period spans July 2025 to February 2026 amid disputed FDA findings
The class covers purchasers of Beta Bionics common stock between July 30, 2025 and February 24, 2026. Investors face a November 3, 2026 deadline to seek appointment as lead plaintiff.
Complaint alleges executives downplayed FDA Form 483 inspection findings
According to the complaint, Beta Bionics disclosed that the FDA had issued a Form 483 following an inspection of its manufacturing facility. Defendants told investors the observations concerned only the criteria for deciding which customer complaints were reportable, involved no underlying device problem, and that newly reportable complaints were minor events requiring no medical intervention.
FDA findings reportedly extended to quality systems and unreported serious injuries
The complaint alleges the FDA's actual findings reached the company's quality management system, its investigation and correction of known device malfunctions, and the risk analysis for the iLet device itself. The unreported events allegedly included serious injuries, not the minor incidents the company had represented to the market.
Stock declined as additional details emerged
Defendants allegedly continued characterizing the FDA's concerns as procedural even as further information showed the unreported events were more serious than represented and that the agency's objections were not limited to a difference in regulatory interpretation. Beta Bionics common stock declined as this information reached the market, according to the complaint.
Law firm seeks lead plaintiff for shareholder class
Schall, Brown & Schwartz LLP is soliciting Beta Bionics shareholders who purchased shares during the class period to determine eligibility to serve as lead plaintiff or to participate in any recovery without out-of-pocket costs. The firm states its attorneys have recovered more than $1 billion in prior securities violation cases.